RESEARCH DIGEST / IV NAD+ · CAUTION
IV NAD+ and Injectable Routes in the Research Literature
An unapproved compounded wellness therapy, read straight from the pharmacokinetic and tolerability findings — including a documented contamination recall.
The short version
IV NAD+ is an intravenous infusion of NAD+ marketed by wellness clinics. It is not FDA-approved, and it has the weakest evidence in the whole NAD+ field. The key finding: when NAD+ is infused, your body clears it from the blood fast — a pilot study saw most of it gone within about two hours [11]. Fast infusions can cause chest pressure, stomach discomfort, and nausea. A compounded injectable NAD+ product was recalled by the FDA for bacterial contamination. This page reports what the studies measured — pharmacokinetics and tolerability — not a verdict that it works, and gives no administration instructions.
What is studied about IV NAD+ therapy
NAD IV therapy delivers NAD+ directly into the bloodstream, bypassing the poor oral absorption of the intact molecule. The controlled evidence is limited and mostly pilot or retrospective [11]. The most-cited pharmacokinetic finding is that infused NAD+ is extensively metabolized and rapidly cleared from plasma, with near-complete removal within roughly the first two hours of infusion [11]. One characterization used a continuous infusion of 3 micromoles per minute over 6 hours to map the NAD+ metabolome [11].
What the literature describes is the pharmacokinetics and the metabolome — how the body handles infused NAD+ — not hard clinical endpoints. There is no cited controlled trial demonstrating that IV NAD+ produces a specific health outcome. That gap is the central fact of this page.
How long does infused or supplemented NAD+ persist?
Infused NAD+ does not linger. A pilot study found infused NAD+ is rapidly cleared from plasma, with near-complete removal within about the first two hours [11]. This is the opposite of the oral-precursor pattern, where blood NAD+ stays elevated across weeks of dosing [4][7]. The short plasma persistence of intact infused NAD+ is one reason the route's mechanism is debated: much of an infusion may be metabolized to precursors and nicotinamide rather than taken up as intact NAD+ [11].
Tolerability and the contamination recall
Infusion tolerability is rate-dependent. When run too fast, IV NAD+ can cause chest and abdominal discomfort, flushing, and nausea; in the controlled IV comparison, infusion-related symptoms resolved on completion of the session. Beyond infusion discomfort, the route carries a documented quality risk: a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin. A Class I recall is the FDA's most serious category, reserved for products that may cause serious harm.
This is the distinction the page exists to make: IV/injectable NAD+ is a compounded therapy, not an FDA-approved drug, and compounded injectables are not subject to the same manufacturing controls as approved products. The endotoxin recall is a concrete instance of that risk, not a hypothetical.
What is an NAD injection?
An NAD injection or IV infusion delivers NAD+ directly into the bloodstream as a compounded wellness therapy. It is not FDA-approved. Pilot pharmacokinetic data show infused NAD+ is rapidly cleared from plasma, and fast infusions can cause discomfort [11]. Subcutaneous and intramuscular NAD+ injections are also compounded, with minimal peer-reviewed pharmacokinetic data.
Is an NAD+ shot worth it?
Controlled evidence for injectable NAD+ is the weakest in the NAD+ literature — mostly pilot and retrospective work characterizing pharmacokinetics, not clinical outcomes [11]. This digest reports those findings rather than a verdict, because the studies measure how the body handles infused NAD+, not whether it delivers a defined benefit. A 2025 review of the broader NAD+ field likewise found human clinical-outcome efficacy still limited [15].
Does NAD IV actually work?
A pilot study found infused NAD+ is extensively metabolized and rapidly cleared from plasma [11]. Controlled efficacy data are limited; the cited work measures the NAD+ metabolome and tolerability, not hard clinical endpoints. So the honest answer is that the literature characterizes what happens to infused NAD+ in the body, but does not establish that IV NAD+ 'works' for a specific outcome [11][15].
When should you inject NAD+?
The cited literature does not establish a timing protocol for injectable NAD+; it characterizes infusion pharmacokinetics and tolerability only [11]. This is a research digest and gives no administration instructions, including timing.